These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1673425)

  • 1. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
    Hasinoff BB; Reinders FX; Clark V
    Drug Metab Dispos; 1991; 19(1):74-80. PubMed ID: 1673425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
    Hasinoff BB
    Drug Metab Dispos; 1993; 21(5):883-8. PubMed ID: 7902252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase.
    Hasinoff BB
    Chirality; 1994; 6(3):213-5. PubMed ID: 8024952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte.
    Hasinoff BB; Venkataram S; Singh M; Kuschak TI
    Xenobiotica; 1994 Oct; 24(10):977-87. PubMed ID: 7900413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
    Hasinoff BB
    Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
    Hasinoff BB
    J Pharm Sci; 1994 Jan; 83(1):64-7. PubMed ID: 8138912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
    Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
    Schroeder PE; Hasinoff BB
    Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
    Hasinoff BB; Aoyama RG
    Drug Metab Dispos; 1999 Feb; 27(2):265-8. PubMed ID: 9929514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
    Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
    Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
    Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
    Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.
    Hasinoff BB; Kala SV
    Agents Actions; 1993 May; 39(1-2):72-81. PubMed ID: 8285144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
    Vile GF; Winterbourn CC
    Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
    Schroeder PE; Hasinoff BB
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.